Handelsavisen
prelaunch
Companies Healthcare UHS
UH
UHS NYSE Medical Equipment & Supplies

Universal Health Services Inc

$169,04
Open in Charts → Attach watcher ⌖
USD
Set alert
LatestThe Week Ahead: 27 July-31 July 2026
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
10,4B USD
P/E
6,3x
EV / Rev
0,8x
Div yield
0,53 %
Op margin
11,5 %
ROE
19,9 %
Net margin
8,6 %
Debt / equity
0,63
Beta
52w range
Volume
Day range
Prev close
$151,27
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Universal Health Services Inc operates healthcare facilities, generating revenue through patient care services and facility management.

Business. Universal Health Services Inc (UHS) is a healthcare company primarily engaged in the medical devices industry, operating within the broader Medical Equipment, Supplies & Distribution sector. The firm generates revenue through a product-sale model and is headquartered in the United States. It is publicly traded on the New York Stock Exchange under the ticker symbol UHS. Specific details regarding operating segments and geographic revenue mix are not available.

Classification70 %
SectorHealthcare
Business sectorHealthcare Equipment & Supplies
Industry groupMedical Equipment, Supplies & Distribution
IndustryMedical Equipment & Supplies
ActivityMedical Devices
Generated · model-assisted
Sell-side consensus
HOLD22 analysts
7 buy14 hold1 sell
Avg 12m price target212,06

Analyst recommendations

22 analysts · consensus Hold
Buy7
Hold14
Sell1
12-month price target
212,06
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
6,3x
P/E
Analysts
Hold
22 analysts · indicative
Ownership
Arrowstreet Capital, Limited Partnership
largest disclosed fund holder
Profitability
19,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

2
  • MARKETSThe Week Ahead: 27 July-31 July 20262026-07-26
  • MARKETSUniversal Health Services files 8-K on material agreements and executive departures2026-07-26
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to UHS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    Universal Health Services Inc (UHS) is undergoing its first formal analysis, establishing a baseline for future performance tracking without prior comparative data. This initial assessment highlights the company's current structural profile, which includes two officers, one index membership, and a shareholder base comprising 34 top holders [doc:uhs-companyfacts]. The absence of previous material change records means that current metrics serve as the foundational reference point for all subsequent financial evaluations. A notable development in the shareholder registry involves a significant modification in holdings by investor ID 931. Data detected on June 25, 2026, indicates that this investor increased their position from 25 shares to 692 shares as of March 31, 2026. This adjustment represents a major severity change in the holder's stake, reflecting a substantial shift in ownership concentration for this specific entity during the reported period. However, conflicting data points suggest volatility or correction in the reporting of this specific holder's position. A separate signal detected on June 24, 2026, shows the reverse movement, with the same investor's holdings recorded as decreasing from 692 shares back to 25 shares for the same March 31, 2026, date. This discrepancy highlights the need for careful verification of shareholder data, as the net change for this investor appears to oscillate between a significant increase and a return to the original low-share count. Despite these shareholder fluctuations, the broader analyst landscape for UHS remains quiet, with zero analysts currently covering the stock. The company continues to maintain its presence in one index and retains its existing officer count. As the first analysis for this ticker, these findings establish the current static and dynamic parameters for UHS, setting the stage for monitoring future material changes against this newly defined baseline.

    Signals & dispatch

    peak dispatch · 2026-07-26

    Composite-score breakdown

    Synthesis

    Business

    Universal Health Services Inc (UHS) is a healthcare company primarily engaged in the medical devices industry, operating within the broader Medical Equipment, Supplies & Distribution sector. The firm generates revenue through a product-sale model and is headquartered in the United States. It is publicly traded on the New York Stock Exchange under the ticker symbol UHS. Specific details regarding operating segments and geographic revenue mix are not available.

    Classification70 %
    SectorHealthcare
    Business sectorHealthcare Equipment & Supplies
    Industry groupMedical Equipment, Supplies & Distribution
    IndustryMedical Equipment & Supplies
    ActivityMedical Devices
    AI synthesis
    GENERATED

    Universal Health Services maintains a capital structure supported by $15.68 billion in total assets and $7.46 billion in equity, with a debt-to-equity ratio of 0.63. The company holds $119.03 million in cash and equivalents against $4.71 billion in total debt, resulting in a negative net cash position. Liquidity is assessed as high, though the current ratio of 1.08 sits close to the minimum comfort range. The firm generated $401.63 million in operating cash flow and $184.47 million in free cash flow during the latest period, supporting its leverage profile.

    Profitability metrics show a return on equity of 19.94% and a return on assets of 9.49%, indicating efficient use of capital. The company trades at a price-to-earnings ratio of 6.27 and an EV/EBITDA of 6.98, suggesting a valuation discount relative to broader market multiples. Operating income of $502.86 million on $4.49 billion in revenue reflects a solid operating margin, while net income of $348.68 million demonstrates consistent earnings generation.

    Universal Health Services Inc (UHS) is undergoing its first formal analysis, establishing a baseline for future performance tracking without prior comparative data. This initial assessment highlights the company's current structural profile, which includes two officers, one index membership, and a shareholder base comprising 34 top holders [doc:uhs-companyfacts]. The absence of previous material change records means that current metrics serve as the foundational reference point for all subsequent financial evaluations. A notable development in the shareholder registry involves a significant modification in holdings by investor ID 931. Data detected on June 25, 2026, indicates that this investor increased their position from 25 shares to 692 shares as of March 31, 2026. This adjustment represents a major severity change in the holder's stake, reflecting a substantial shift in ownership concentration for this specific entity during the reported period. However, conflicting data points suggest volatility or correction in the reporting of this specific holder's position. A separate signal detected on June 24, 2026, shows the reverse movement, with the same investor's holdings recorded as decreasing from 692 shares back to 25 shares for the same March 31, 2026, date. This discrepancy highlights the need for careful verification of shareholder data, as the net change for this investor appears to oscillate between a significant increase and a return to the original low-share count. Despite these shareholder fluctuations, the broader analyst landscape for UHS remains quiet, with zero analysts currently covering the stock. The company continues to maintain its presence in one index and retains its existing officer count. As the first analysis for this ticker, these findings establish the current static and dynamic parameters for UHS, setting the stage for monitoring future material changes against this newly defined baseline.

    Key takeaways
    • The company trades at a significant valuation discount with a P/E of 6.27 and EV/EBITDA of 6.98.
    • Strong profitability with ROE of 19.94% and ROA of 9.49% indicates efficient capital use.
    • Liquidity is high but constrained by a current ratio of 1.08 and negative net cash position.
    • Strategic growth through the acquisition of Talkspace, Inc., supported by increased borrowing capacity.
    • Medium dilution risk and regulatory compliance challenges pose potential headwinds.
    • Analyst sentiment is positive with a mean price target of $212.06, suggesting upside potential.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 3

    Net income CAGR of 26.1% from FY2023 to FY2025 demonstrates strong earnings growth momentum.

    Long-term debt decreased to $4.0 billion in FY2025, reflecting a deleveraging trend from prior years.

    Interest coverage ratio of 12.8 indicates strong ability to service debt obligations with operating income.

    BEAR CASE · 4

    Net income fell 23.3% year-over-year in FY2025, indicating significant earnings volatility.

    The company faces a high level of liquidity risk according to current risk flag assessments.

    Debt-to-equity ratio of 0.63 places the company in the bottom quartile of its peer cohort.

    Free cash flow dropped to $849 million in FY2025 from $1.1 billion in FY2024.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-31
    Q4 2025 · Quarter highlights
    Open report →

    Revenue $4.50B; Operating income $502.9M.

    Revenue$4.50B
    Operating income$502.9M
    Net income$348.7M
    Free cash flow$184.5M
    EPS
    Operating cash flow$401.6M
    Financials
    Income statement
    Revenue$4.50B
    Gross profit
    Operating income$502.9M
    Net income$348.7M
    Margins
    Gross margin
    Operating margin11.2%
    Net margin7.8%
    FCF margin4.1%
    Balance sheet
    Total assets$15.68B
    Total liabilities
    Total equity$7.46B
    Cash & equivalents$119.0M
    Long-term debt$3.95B
    Cash flow
    Operating cash flow$401.6M
    CapEx$217.2M
    Free cash flow$184.5M
    SBC$22.5M
    P&L flow · revenue → net income
    Revenue $4.50BOperating costs $3.99BTax $154.2MNet income $348.7M
    Highlights
    • Revenue $4.50B
    • Operating income $502.9M
    • Net margin 7.8%

    Valuation FY

    Market price
    $169,04
    Market cap
    $9.33B
    Enterprise value
    $13.92B
    P/E
    6.3x
    Non-GAAP P/E
    EV / Revenue
    0.8x
    EV / Op income
    7.0x
    EV / OCF
    7.5x
    P / B
    P / Tangible book
    Tangible book
    Net cash
    -$4.59B
    Current ratio
    1.1
    Debt / equity
    0.6
    ROA
    9.5%
    ROE
    19.9%
    Cash conversion
    125.0%
    CapEx / revenue
    5.9%
    SBC / revenue
    0.5%
    Dilution ratio

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate23,40
    Revenueno estimateno estimate18,5B USD
    Operating incomeno estimateno estimate2,0B USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Corporate eventM&A horizon
    M&A probabilityconf 3 %
    Probability
    3 %
    Base rate
    3 %
    Band
    180-day horizon · target 2027-01-20 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-07-24

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution21 analysts
    Strong buy2
    Buy6
    Hold12
    Sell1
    Strong sell0
    12-month price target$226,16 · Median $221,74
    Low $190,00High $310,00
    Operating income · consensus2,0B USD
    EPS surprise
    −7,1 %
    reported vs consensus · miss
    Revenue surprise
    −6,2 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$166,00
    Mean$212,06
    Median$204,50
    High$310,00
    Spot$169,04
    +25.5 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskMedium
    Liquidity riskHigh
    Filing-based flags
    • Current ratio is close to the minimum comfort range.
    • Net cash is negative after subtracting total debt.
    • Source documents mention dilution or offering risk.

    Benchmarks vs cohort

    Op Margin11,5 %Above median
    Net Margin8,6 %Above median
    ROE19,9 %Above median
    Capex / Rev5,9 %Above median
    D/E0,63Bottom quartile
    Cash Conv1,25Above median

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    3 %
    Base rate
    3 %
    Band
    Low
    180-day horizon · target 2027-01-20 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net disposed 331 374 sh10 exercises6 insiders
    • SUSSMAN ELLIOT J MD MBADirector · Option To Purchase Class B Common Stock → Class B Common StockDisposed 1 250 @ $138,80exercise · 2026-03-13
    • Singer Maria RudermanDirector · Option To Purchase Class B Common Stock → Class B Common StockDisposed 2 500 @ $138,80exercise · 2026-03-12
    • FILTON STEVEExecutive Vice President & CFO · Option To Purchase Class B Common Stock → Class B Common StockDisposed 44 037 @ $152,68exercise · 2026-03-12
    • Miller Marc DDirector, President and CEO · Option To Purchase Class B Common Stock → Class B Common StockDisposed 50 425 @ $152,68exercise · 2026-03-12
    • FILTON STEVEExecutive Vice President & CFO · Option To Purchase Class B Common Stock → Class B Common StockDisposed 39 200 @ $138,80exercise · 2026-03-12
    • Miller Marc DDirector, President and CEO · Option To Purchase Class B Common Stock → Class B Common StockDisposed 50 000 @ $138,80exercise · 2026-03-12
    • SUSSMAN ELLIOT J MD MBADirector · Option To Purchase Class B Common Stock → Class B Common StockDisposed 1 250 @ $138,80exercise · 2026-03-11
    • MILLER ALAN BDirector, Executive Chairman, 10% owner · Option To Purchase Class B Common Stock → Class B Common StockDisposed 62 500 @ $138,80exercise · 2026-03-10
    • MILLER ALAN BDirector, Executive Chairman, 10% owner · Option To Purchase Class B Common Stock → Class B Common StockDisposed 70 212 @ $152,68exercise · 2026-03-10
    • Nimetz Warren J.Director · Option To Purchase Class B Common Stock → Class B Common StockDisposed 10 000 @ $138,80exercise · 2025-11-11

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Regulatory filings
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Enterprise Value
      market_cap - net_cash
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Capex To Revenue
      capital_expenditure / revenue
    Source documents
    • UNIVERSAL HEALTH SERVICES INC company facts · 2026-07-26
    • UNIVERSAL HEALTH SERVICES INC 10-Q 2026-05-07 · 2026-07-26
    • UNIVERSAL HEALTH SERVICES INC 10-K 2026-02-25 · 2026-07-26
    • UNIVERSAL HEALTH SERVICES INC 10-Q 2025-11-07 · 2026-07-26
    • UNIVERSAL HEALTH SERVICES INC 10-Q 2025-08-08 · 2026-07-26
    • 8-K (sec_8k_material) on UHS · 2026-07-26
    • Universal Health Services Inc Market data — analyst estimates · 2026-07-26
    • Universal Health Services Inc Market data — ESG · 2026-07-26

    Ownership & reference

    Top holders

    • Arrowstreet Capital, Limited PartnershipInvestment Managers · as of 2026-03-310,12 %$220M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,08 %$149M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,07 %$319M
    • MASSACHUSETTS FINANCIAL SERVICES CO /MA/Institutional Investor · as of 2026-03-310,05 %$160M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,05 %$105M
    • Invesco QQQ TrustFunds · as of 2026-03-310,04 %$284M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,03 %$238M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,02 %$31M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,02 %$348M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,02 %$1 414M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,02 %$822M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,02 %$462M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,02 %$104M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,01 %$95M
    • FMR LLCInstitutional Investor · as of 2026-03-310,01 %$235M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,01 %$67M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,01 %$15M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,01 %$49M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,01 %$35M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,01 %$25M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,01 %$25M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,01 %$111M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,01 %$12M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$24M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$13M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$17M
    • EATON VANCE MANAGEMENTInstitutional Investor · as of 2022-09-300,00 %$0M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$8M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$6M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$2M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$1M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

    Leadership

    • Alan B. MillerExecutive Chairman of the Board
    • Marc D. MillerPresident, Chief Executive Officer, Director

    Insider activity

    Net selling0 buys · 4 sellsnet -$980K10 insiders · last 365d
    • MILLER ALAN BDirector, Executive Chairman, 10% owner · Class B Common StockOther 14 163 · 2026-05-27
    • MILLER ALAN BDirector, Executive Chairman, 10% owner · Class B Common StockOther 25 495 · 2026-05-27
    • MILLER ALAN BDirector, Executive Chairman, 10% owner · Class B Common StockOther 13 963 · 2026-05-27
    • MILLER ALAN BDirector, Executive Chairman, 10% owner · Class B Common StockOther 9 418 · 2026-05-27
    • MILLER ALAN BDirector, Executive Chairman, 10% owner · Class B Common StockOther 50 990 · 2026-05-27
    • Nimetz Warren J.Director · Class B Common StockOther 1 217 · 2026-05-20
    • Singer Maria RudermanDirector · Class B Common StockOther 1 217 · 2026-05-20
    • McDonnell Eileen C.Director · Class B Common StockOther 1 217 · 2026-05-20
    • SUSSMAN ELLIOT J MD MBADirector · Class B Common StockOther 1 217 · 2026-05-20
    • Chen-Langenmayr NinaDirector · Class B Common StockOther 1 217 · 2026-05-20
    • MILLER ALAN BDirector, Executive Chairman, 10% owner · Class B Common StockOther 14 153 · 2026-03-26
    • Miller Marc DDirector, President and CEO · Class B Common StockOther 29 715 · 2026-03-26
    • FILTON STEVEExecutive Vice President & CFO · Class B Common StockOther 6 850 · 2026-03-26
    • Sim Edward HExecutive Vice President · Class B Common StockOther 6 404 · 2026-03-26
    • Peterson Matthew JayExecutive Vice President, UHS · Class B Common StockOther 5 627 · 2026-03-26
    • FILTON STEVEExecutive Vice President & CFO · Class B Common StockOther 616 @ $185,82$114K · 2026-03-21
    • Miller Marc DDirector, President and CEO · Class B Common StockOther 2 239 @ $185,82$416K · 2026-03-21
    • Peterson Matthew JayExecutive Vice President, UHS · Class B Common StockOther 512 @ $185,82$95K · 2026-03-21
    • Sim Edward HExecutive Vice President · Class B Common StockOther 593 @ $185,82$110K · 2026-03-21
    • MILLER ALAN BDirector, Executive Chairman, 10% owner · Class B Common StockOther 1 177 @ $185,82$219K · 2026-03-21
    • FILTON STEVEExecutive Vice President & CFO · Class B Common StockOther 731 @ $189,58$139K · 2026-03-19
    • MILLER ALAN BDirector, Executive Chairman, 10% owner · Class B Common StockOther 1 399 @ $189,58$265K · 2026-03-19
    • Miller Marc DDirector, President and CEO · Class B Common StockOther 2 762 @ $189,58$524K · 2026-03-19
    • Peterson Matthew JayExecutive Vice President, UHS · Class B Common StockOther 608 @ $189,58$115K · 2026-03-19
    • Sim Edward HExecutive Vice President · Class B Common StockOther 704 @ $189,58$133K · 2026-03-19

    Short positioning

    3.4Mshares short+12.6% vs prior
    3.78days to cover
    69.1%short of daily vol
    4.5Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)
    Index membership
    S&P 500United States

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    UHSCanonical
    NYSE · USD

    Intel & risk

    PredictorM&A prob3 %Full forecast →
    What changed

    no material change vs prior analysis (walked 17 fields; 4 schema-expansion field(s) excluded)

    • Narrative— → —medium
    • Conclusion— → —medium
    • Company share pct— → —medium
    vs prior analysis today
    peak dispatch · 2026-07-26
    OSINT findings
    Dilution riskMedium
    Liquidity riskHigh
    Current ratio is close to the minimum comfort range.
    Net cash is negative after subtracting total debt.
    Source documents mention dilution or offering risk.

    Evidence & claims

    From filings & derived data
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 9.7%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 18.6%Derived (calculated)
    • Return on assets (FY 2025-12-31): 9.6%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 37.3%Derived (calculated)
    • Net margin (FY 2025-12-31): 8.6%Derived (calculated)
    • Current ratio (FY 2025-12-31): 1.05xDerived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 30.4%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 9.1%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 36.5%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 7.6%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 7.3%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 9.4%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -9.8%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 6.6%Derived (calculated)
    • Return on equity (FY 2025-12-31): 20.5%Derived (calculated)
    • EPS (diluted) (annual): USD-PER-SHARES 23SEC XBRL filing
    • Interest expense (annual): USD 156.07MSEC XBRL filing
    • Pre-tax income (annual): USD 1.97BSEC XBRL filing
    • Revenue (annual): USD 17.36BSEC XBRL filing
    • Net income (annual): USD 1.49BSEC XBRL filing
    • Operating cash flow (annual): USD 1.86BSEC XBRL filing
    • Capex (annual): USD 1.02BSEC XBRL filing
    • Current liabilities (annual): USD 3.24BSEC XBRL filing
    • Current assets (annual): USD 3.41BSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-29 04:35 UTCFILINGMaterial 8-K
    2026-07-27 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-07-27EVENTQ2 2026 earnings (expected) estimated date
    2026-07-22 04:25 UTCFILINGMaterial 8-K
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-25 03:10 UTCHOLDERInstitutional holding changed
    2026-06-25 03:10 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-24 03:12 UTCHOLDERInstitutional holding changed
    2026-06-24 03:12 UTCHOLDER1 institutional position change flagged (1 major)
    2026-05-27 00:00 UTCINSIDER10 insider transactions — 2026-05
    2026-05-27 00:00 UTCINSIDER10 insider transactions — 2026-05
    2026-05-27INSIDERMILLER ALAN B transacted 14.2k sh Class B Common Stock — Director, Executive Chairman, 10% owner
    2026-05-27INSIDERMILLER ALAN B transacted 25.5k sh Class B Common Stock — Director, Executive Chairman, 10% owner
    2026-05-27INSIDERMILLER ALAN B transacted 14.0k sh Class B Common Stock — Director, Executive Chairman, 10% owner
    2026-05-27INSIDERMILLER ALAN B transacted 9.4k sh Class B Common Stock — Director, Executive Chairman, 10% owner
    2026-05-27INSIDERMILLER ALAN B transacted 51.0k sh Class B Common Stock — Director, Executive Chairman, 10% owner
    2026-05-22FILING8-K filing →
    2026-05-21FILING8-K filing →
    2026-05-20INSIDERNimetz Warren J. transacted 1.2k sh Class B Common Stock — Director
    2026-05-20INSIDERSinger Maria Ruderman transacted 1.2k sh Class B Common Stock — Director
    2026-05-20INSIDERMcDonnell Eileen C. transacted 1.2k sh Class B Common Stock — Director
    2026-05-20INSIDERSUSSMAN ELLIOT J MD MBA transacted 1.2k sh Class B Common Stock — Director
    2026-05-20INSIDERChen-Langenmayr Nina transacted 1.2k sh Class B Common Stock — Director
    2026-05-07FILING10-Q filing →
    2026-05-01 10:36 UTCFILINGRegulatory filing →
    2026-04-28FILING8-K filing →
    2026-04-24FILING8-K filing →
    2026-04-09FILINGDEF 14A filing →
    2026-03-31EARNINGSQuarterly results — Q4 2025 Revenue USD 4.50B · Net USD 348.7M
    2026-03-30FILING8-K filing →
    2026-03-26 00:00 UTCINSIDER51 insider transactions — 2026-03 · net sell $18.8M 9 derivative
    2026-03-26 00:00 UTCINSIDER51 insider transactions — 2026-03 · net sell $18.8M 9 derivative
    2026-03-26INSIDERMILLER ALAN B transacted 14.2k sh Class B Common Stock — Director, Executive Chairman, 10% owner
    2026-03-26INSIDERMiller Marc D transacted 29.7k sh Class B Common Stock — Director, President and CEO
    2026-03-26INSIDERFILTON STEVE transacted 6.8k sh Class B Common Stock — Executive Vice President & CFO
    2026-03-26INSIDERSim Edward H transacted 6.4k sh Class B Common Stock — Executive Vice President
    2026-03-26INSIDERPeterson Matthew Jay transacted 5.6k sh Class B Common Stock — Executive Vice President, UHS
    Showing the 40 most recent of 73 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage